Impact of CYP2D6 and CYP2B6 phenotypes on the response to tramadol in patients with acute post-surgical pain

Clin Transl Sci. 2023 Dec 22. doi: 10.1111/cts.13698. Online ahead of print. ABSTRACT Tramadol is an important minor opioid prescribed for pain management. In this work, we analyzed the well-known impact of CYP2D6 genetic variation and 60 additional variants in eight candidate genes (i.e., ABCG2, SLCO1B1, CYP2D6, CYP2B6, CYP2C19, CYP2C9, CYP3A5 and CYP3A4) on tramadol…

Use of glucarpidase (carboxypeptidase-G2) in pediatric cancer patients: 11-year experience of a tertiary center

EJHaem. 2023 Sep 27;4(4):1052-1058. doi: 10.1002/jha2.799. eCollection 2023 Nov. ABSTRACT Methotrexate is an essential drug in the treatment of childhood cancer that is not exempt from toxicities. Glucarpidase is a drug used to reduce the toxic concentration of plasma methotrexate in patients with delayed elimination or at risk of toxicity. We describe the characteristics of…

Food Administration and Not Genetic Variants Causes Pharmacokinetic Variability of Tadalafil and Finasteride

J Pers Med. 2023 Oct 31;13(11):1566. doi: 10.3390/jpm13111566. ABSTRACT Tadalafil and finasteride are used in combination for the management of benign prostatic hyperplasia (BPH). Genetic variations in genes involved in the metabolism and transport of tadalafil or finasteride (i.e., pharmacogenes) could affect their pharmacokinetic processes altering their drug exposure, efficacy, and toxicity. The main objective…

La Integración de Análisis Genéticos Predictivos en la Cartera del SNS

La reciente aprobación de la actualización de la cartera de servicios comunes de atención especializada en el marco del Sistema Nacional de Salud (SNS) ha dado lugar a la integración de análisis genéticos predictivos como una herramienta fundamental. Estos análisis son aplicados de manera específica en individuos que requieren la administración de ciertos medicamentos contemplados…

Impact of Sex and Genetic Variation in Relevant Pharmacogenes on the Pharmacokinetics and Safety of Valsartan, Olmesartan and Hydrochlorothiazide

Int J Mol Sci. 2023 Oct 17;24(20):15265. doi: 10.3390/ijms242015265. ABSTRACT Drug combination therapy is the most common pharmacological strategy for hypertension management. No pharmacogenetic biomarkers for guiding hypertension pharmacotherapy are available to date. The study population were 64 volunteers from seven bioequivalence trials investigating formulations with valsartan, olmesartan and/or hydrochlorothiazide. Every volunteer was genotyped for…

Frecuencias de alelos farmacogenómicos entre grupos biogeográficos en el biobanco del Reino Unido

Para garantizar la eficacia de la farmacogenética en la atención clínica, es esencial considerar diversos haplotipos/diplotipos. El auge de los biobancos genéticos a nivel mundial ofrece la oportunidad de comprender las frecuencias de distintos alelos farmacogenéticos en diversas poblaciones. En este estudio (Li B, et al. Frequencies of pharmacogenomic alleles across biogeographic groups in a…

Academia and industry agreement on a feasibility tool for first-time-in-human clinical trial units

Clin Transl Sci. 2023 Oct 11. doi: 10.1111/cts.13655. Online ahead of print. ABSTRACT First-time-in-human (FTIH) trials are designed to generate information on the safety, tolerability, as well as the pharmacokinetic and pharmacodynamics profile of new drugs. To ensure the safety of participants, these trials need to be conducted at specifically equipped phase I clinical trial…

Occurrence of SARS-CoV-2 viremia is associated with genetic variants of genes related to COVID-19 pathogenesis

Front Med (Lausanne). 2023 Sep 22;10:1215246. doi: 10.3389/fmed.2023.1215246. eCollection 2023. ABSTRACT INTRODUCTION: SARS-CoV-2 viral load has been related to COVID-19 severity. The main aim of this study was to evaluate the relationship between SARS-CoV-2 viremia and SNPs in genes previously studied by our group as predictors of COVID-19 severity. MATERIALS AND METHODS: Retrospective observational study…

Impacto del haplotipo CYP2C:TG en el aclaramiento in vivo, concentración proteica y la actividad in vitro de sustratos de CYP2C19

Recientemente, se ha asociado un nuevo haplotipo compuesto por dos variantes no codificantes, CYP2C18 NM_000772.3:c.*31T (rs2860840) y NM_000772.2:c.819+2182G (rs11188059), denominado “CYP2C:TG”, con el metabolismo ultrarrápido de varios sustratos de CYP2C19. Dado que el mecanismo subyacente y la relevancia clínica de este efecto siguen siendo inciertos, en este trabajo analizamos datos in vivo e in vitro…